Exscientia, a pioneer in the use of Artificial Intelligence (AI) in drug discovery and one of Frontier’s core portfolio companies, has announced that it has raised US$26m in a Series B funding round which includes participation from new investors Celgene Corporation and GT Healthcare Capital Partners, as well as from existing investor Evotec AG. It has also announced a drug discovery collaboration with Roche worth up to CHF 67m in upfront and research funding. Post the funding round Frontier’s s ....
08 Jan 2019
Positive news from portfolio company Exscientia
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Positive news from portfolio company Exscientia
Frontier IP Group Plc (FIPP:LON) | 38.5 0 0.0% | Mkt Cap: 21.6m
- Published:
08 Jan 2019 -
Author:
Ian Jermin -
Pages:
3
Exscientia, a pioneer in the use of Artificial Intelligence (AI) in drug discovery and one of Frontier’s core portfolio companies, has announced that it has raised US$26m in a Series B funding round which includes participation from new investors Celgene Corporation and GT Healthcare Capital Partners, as well as from existing investor Evotec AG. It has also announced a drug discovery collaboration with Roche worth up to CHF 67m in upfront and research funding. Post the funding round Frontier’s s ....